Millions of men stand to benefit from a discovery by UCL scientists that could provide a breakthrough in the treatment of enlargement of the prostate (BPH). The UCL team has developed a new drug, Rho-kinase inhibitor that, in preliminary tests, has been found to treat the condition by both relaxing the prostate and stopping the growth of cells within it. Their findings are set out in the current issue of the Journal of Urology.

BPH affects approximately 85% of men over the age of 50 and causes frequent urination and irritation due to the obstruction of urine flow. The drugs currently available for treatment of BPH aim to either relax the prostrate or to reduce its size as two separate actions, and also have undesired hormonal effects. These effects, along with the need to take two separate treatments, often lead to problems of patient compliance. The discovery by the UCL scientists is novel in that this new drug can both relax the prostate and stop it from growing, with virtually no hormonal side effects.

Dr Selim Cellek, who led the investigation as a collaborative work between UCL's Wolfson Institute for Biomedical Research and its Institute of Urology and Nephrology, said: "We are very excited by this discovery, as it is a medical breakthrough which represents a major advance in treating a condition that affects such a large proportion of the population. We are still at the development stages and more research will be required before the new treatment becomes available. The next step will be to develop links with investors interested in developing this drug for the treatment of BPH.

"Research has shown that this type of compound can also be used to treat erectile dysfunction (impotence). The future for this line of research is therefore promising since men with an enlarged prostate often suffer from impotence. "

Malcolm Grant, UCL Provost, said: "The conversion of scientific results into new medicines is one of the main aims of th
'"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-207-679-9728
University College London
27-Nov-2003

Page: 1 2
Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Chronic pain treatments more effective when taken together, new study shows
4. Brain activity prior to treatment flags vulnerability to antidepressant side effects
5. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
6. OHSU scientists test medication to treat involuntary weight loss
7. Cultural and social factors influence prostate cancer treatment
8. Research offers hope of new treatments for liver damage
9. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
10. Risky surgery not always necessary to treat cervical disease
11. Stanford patient is first to test new treatment for peripheral arterial disease